Breaking News

TAP Biosystems Approves Sartorius Takeover

November 22, 2013

Expands Sartorius’ bioprocess portfolio in fermentation

The shareholders of TAP Biosystems Group have approved Sartorius Stedim Biotech’s takeover offer valued at approximately $44 million. The transaction is expected to close at the end of the year.
The acquisition expands Sartorius’ bioprocess portfolio in the area of fermentation, particularly in the early phases of product and process development. TAP Biosystems, headquartered in Royston, UK, specializes in the design and development of small scale, multi-parallel fermentation and cell culture systems for biopharmaceutical applications. TAPs’ portfolio includes automated cell processing systems and other benchtop equipment. TAP Biosystems generated sales revenue of approximately $35 million in 2012-13 and has approximately 160 employees worldwide.

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks